Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine modelAmerican Journal of Obstetrics and Gynecology
NLM Title AbbreviationAm J Obstet Gynecol
DOI of Published Version10.1016/j.ajog.2011.06.024
AbstractOBJECTIVE: The purpose was to examine in mice the efficacy of various polymeric-encapsulated C5a peptidase vaccine formulations in eliciting a long-term immune response and preventing group B streptococcus (GBS) infection. STUDY DESIGN: C5a peptidase was encapsulated in semipermeable microspheres of poly(lactide-coglycolide) (PLGA). Female ICR mice were immunized with 0, 10, or 30 mug of encapsulated C5a peptidase within 2 different formulations of PLGA polymers. Booster doses were given at weeks 4 and 8. Antibody responses were measured by enzyme-linked immunosorbent assay at weeks 4, 8, 11, and 40. Vaginal challenges with GBS types 1a, III, and V were performed at week 12. RESULTS: Thirty microgram doses of the 75:25 and 50:50 PLGA formulations generate the highest and most sustained C5a peptidase-specific immune responses. Mice that received encapsulated C5a peptidase were significantly protected from vaginal colonization compared with mice that received empty microspheres. CONCLUSION: Encapsulated C5a peptidase elicited significant immune responses and protection against a GBS challenge. C5a peptidase microsphere encapsulation has potential as a GBS vaccine.
- Inbred ICR,
- Streptococcal Infections/prevention & control,
- Streptococcal Vaccines/immunology,
- Streptococcus agalactiae/immunology
Published Article/Book CitationAmerican Journal of Obstetrics and Gynecology, 205:3 (2011) pp.249.e1-249.e8.
Citation InformationDonna A. Santillan, K. K. Rai, Mark K. Santillan, Y. Krishnamachari, et al.. "Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model" American Journal of Obstetrics and Gynecology Vol. 205 Iss. 3 (2011) p. 249.e1 - 249.e8 ISSN: 1097-6868
Available at: http://works.bepress.com/mark_santillan/15/